Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA

This publication has 38 references indexed in Scilit:

• Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending
  JAMA Internal Medicine, 2017
• Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients
  Neurology Clinical Practice, 2016
• The Patient Protection and Affordable Care Act and Chronic Neurological Illnesses
  JAMA Neurology, 2015
• Drug Companies' Patient-Assistance Programs — Helping Patients or Profits?
  New England Journal of Medicine, 2014
• The cost burden of multiple sclerosis in the United States: a systematic review of the literature
  Journal of Medical Economics, 2013
• Immune mechanisms of new therapeutic strategies in MS — Teriflunomide
  Clinical Immunology, 2012
• Persistence with biologic therapies in the Medicare coverage gap.
  2011
• Cost-effectiveness of disease-modifying therapy for multiple sclerosis
  Neurology, 2011
• Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis
  Clinical Drug Investigation, 2010
• Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs
  Journal of Medical Economics, 2009